A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC is a phase 3 interventional study registered as NCT06754644, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Randomised, Double-blind, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of QL2107 Versus Keytruda® in Combination With Chemotherapy in the Treatment of Metastatic Non-squamous Non-small-cell Lung Cancer. Planned enrolment is 808 participants (estimated). The study started in 2025-01-15 and primary completion is expected in 2026-12. No results have been posted on ClinicalTrials.gov.